Transcript View

Solid Tumors
Anthony W. Stephens, M.D.
2017
1
Cancer






Characteristics
– abnormal cell growth
– spread/metastasis
– leads to death
Incidence (U.S)
– 1.7 million/year
– 600,000 deaths (1640/day, 68/hour, 1/minute)
– 77% of all cancers in age >55
Survival approximately 69% at 5 years
– Was 49% in the 1970’s
2nd leading cause of death in the US
Accounts for 1 of every 4 deaths
Lifetime risk: 42% male and 38% female
2
Cancer Causes

External Factors
– Tobacco
– Infectious organisms
– Poor diet / lack of exercise

Internal Factors
– Genetic mutations
– Influence of hormones
– Immune conditions
3
Cancer Prevention

At least 30% of cancer cases are preventable

Tobacco, alcohol, obesity, poor nutrition

Infections (HPV, HBV, HCV, HIV, H. pylori)

Sun exposure, tanning beds
4
Cancer Screening

Early detection/stage

May result in less aggressive therapy

Better prognosis?

Proven benefit (breast, colorectal, cervix,
lung)
5
Screening Guidelines

ACS screening guidelines found on page
66 of Cancer Facts & Figures 2016
6
Breast Cancer

Most common cancer in U.S. women

Second leading cause of cancer deaths

Stable incidence 2003 - 2012

1 out of 8 women affected in their lifetime

Can also affect men (1%)
7
Breast Cancer

Scope
– 247,000 cases/year
– 40,890 deaths/year

Incidence highest in North America and
Europe, lowest in Asia and Africa

Mortality declining by 2% since 1990’s
– Overall decline of 36% since 1989

2.9 million survivors living in U.S. today
8
Breast Ca: Etiology

Risk factors:
–
–
–
–
–
–
–
–
–
–
family history/genetics
Increasing age/gender
hormonal factors
diet/lifestyle (obesity/inactivity)
Weight gain after age 18
Radiation exposure
alcohol intake (>1/day)
high breast density
High bone mineral density
LCIS in either breast
9
Breast Ca: Etiology

Hormonal Factors
–
–
–
–
–

Early menarche
Late menopause
Nulliparity
1st pregnancy> 30 years
Menopausal hormone therapy (MHT)
Protective Factors
–
–
–
–
–
Breastfeeding
Avoid weight gain
Limit alcohol
Exercise – regular moderate
Tamoxifen / Raloxifene
10
Types of Breast Cancer

Ductal

Lobular

In situ vs. Invasive

Less common (mucinous, tubular,
metaplastic)

Inflammatory (1-2%)


Very aggressive, red/swollen/inflamed
Paget’s disease
11
Breast Cancer: Genetics

Positive family history in 15-20% of
patients (most patients do not have a
family history)

Do not neglect paternal family history

RR:
– one 1st degree = 1.8
– two 1st degree = 3

Only 5-10% of breast cancer are due to
specific mutation (e.g. BRCA 1 or 2)
12
Breast Ca: Etiology
Genetics: BRCA 1 mutation
– Accounts for 5% of breast CA
– chromosome 17 short arm
– characteristics:
 early age, bilateral disease
 autosomal dominant
 cumulative risk
 ovarian cancer
 high penetrance
 BRCA 2 mutation




Autosomal dominant
Generally lower risk for breast/ovary cancer than with BRCA1 mutation
Men may be carriers
13
BRCA Testing

Criteria
Counseling
 Psychosocial effects


Interventions / Prophylactic Surgery
(mastectomy, oophorectomy, drugs,
more aggressive screening)
14
Breast Ca: Presentation

Usually asymptomatic (mammogram)

Palpable, painless lump- most benign

Thickening, dimpling, erythema, nipple
retraction or discharge, bleeding, or
persistent pain

Role of mammogram, u/s, biopsy, MRI

Only 5% present with metastases
15
Breast Ca: Screening
Mammography






Proven to reduce mortality
ACS recommendations: age 40-44 optional, 4554 annual, >55 biennial or choice of annual
Increase discovery of early stage CA
(? Some overdiagnosis)
False negative rate of 10-15% (particularly in
dense breasts)
Does not substitute for biopsy
Risk of false positive result
16
Breast Ca: Screening
Monthly self breast exam
 Annual physician exam
 Role of genetic testing
 Ultrasound – breast density
 MRI

– High risk women (e.g. BRCA)
– In addition to mammography
17
Breast Ca: Treatment

Surgery - lumpectomy vs. mastectomy (+/reconstruction)

Sentinel node biopsy

Adjuvant chemotherapy/radiation

Hormonal therapy: Tamoxifen, Aromatase
inhibitors
(e.g. – Anastrazole)

Targeted Therapies (Herceptin, Perjeta)
18
Breast Ca: Prognosis

Five year survival: 84-98% for
localized/regional disease

Five year survival: 24% for metastatic disease

Factors: size, lymph node involvement, grade,
hormone receptors, Her2Neu, molecular /gene
expression

Risk of late relapse
19
Lung Cancer: Facts
Incidence:
 Second most common in both sexes
 Leading cause of cancer deaths in males
and females
 224,000/ year diagnosed in US
 158,000 deaths/year in US
 Declining incidence and mortality in males
> females
20
Lung Cancer: Facts

Survival
– 44% at 1 year
– 17% at 5 years

Accounts for 14% of cancer diagnoses,
28% of cancer deaths

Small advances in recent years
21
Lung Ca: Etiology

Tobacco use causes 80% of cases

Risk increases with pack years

Occupational / Second hand exposure

Associated Ca’s: larynx, oral cavity, pharynx,
esophagus, bladder, cervix, pancreas

Other RF’s: age, asbestos, radon

RR 20-30 in smokers

Some genetic susceptibility
22
Lung Cancer: Type

Adenocarcinoma = 35-45%

Squamous Cell = 20-30%

Large Cell = 10%

Small Cell = 15%
23
Lung Ca: Presentation

Few “early” symptoms

Persistent cough, pneumonia, hoarseness, hemoptysis,
dyspnea, chest pain, bone pain, weight loss

Abnormal chest x-ray (10% of patients)

Paraneoplastic Syndromes (e.g. Ca++, SIADH, clubbing)
24
Lung Ca: Screening

Chest x-ray, sputum cytology
– No benefit

Low dose spiral chest CT
– 20% mortality reduction in current or recent
heavy smokers (>30 pack year) age 55-74
25
Lung Ca: Diagnosis

Abnormal chest x-ray

Chest/abdomen CT scan

Bronchoscopy/ biopsy

Staging (e.g.: head CT, bone scan)

PET scan
26
Lung Ca: Treatment

Defined by type and stage

Surgical resection, if feasible

Radiation/chemotherapy

Survival
– Dependent on Stage, health of patient

Targeted therapy (e.g. Tarceva, Avastin, Xalkori)

Immunotherapy
27
Lung Ca: Treatment
DON’T SMOKE!
28
Prostate Ca: Facts

Most common cancer in U.S. males (180,000/year)

Incidence spiked in 1990’s due to PSA

Incidence higher in African Americans vs white

Mortality rates have been declining since 1990’s

Second leading cause of cancer death in men
(29,000/year)
29
Prostate Ca: Risk Factors

Associated with advanced age

> 80% diagnosed beyond age 65

Highest incidence in African-Americans
– Younger age at diagnosis

Family history / genetics (5-10% cases)

High saturated fat diet

Chemoprevention – Finasteride/Dutasteride not
approved, ᴓ survival improvement
30
Prostate Ca: Presentation

Many are asymptomatic (PSA Screen)

Difficulty with urination, hematuria,
nocturia, dysuria

Bone pain from metastasis
31
Prostate Ca: Evaluation

Digital rectal exam (DRE)

Trans-rectal ultrasound, biopsy

PSA, alk phos

Pelvic CT, bone scan

Abdomen/pelvis CT, Bone scan
32
Prostate Ca: Treatment

Dependent upon stage, age, medical condition

Options include surgery and radiation for localized
disease, Immunotherapy, Radiopharmaceutical

Hormonal therapy, chemotherapy for advanced
disease

“Active Surveillance” or “Watchful Waiting”
appropriate for low grade tumors and for older men

Impact of treatment on QOL remains a concern
33
Prostate Ca: Survival

Dependent upon stage at diagnosis, grade
of tumor, medical condition

Metastasis usually involves bones

Survival can be very long

5 year (99%), 15 years (93%)
34
Prostate Ca: Screening
Highly controversial
 No organizations presently endorse
routine prostatic cancer screening for men
at average risk due to concerns regarding
high rate of overdiagnosis and potential
for SE’s associated with treatment of
prostate cancer.
 ACS recommends discussion of PSA
testing with doctor at age 50

35